Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
14C-IVA337Carbon-14-labeled IVA337 (lanifibranor)
1H-MRS, ¹H-MRSProton magnetic resonance spectroscopy
A3, A4SAF activity score of 3, of 4
AAAfrican American
AASLDAmerican Association for the Study of Liver Diseases
ADAAmerican Diabetes Association
Adipo-IRAdipose tissue insulin resistance index
ADPAdiponectin
AE, AEsAdverse event
AESIsAdverse events of special interest
AFwCAdvanced fibrosis (stage 3 to 4) with additional cardiovascular, renal, and metabolic comorbidities
AGAAmerican Gastroenterological Association
AHAAmerican Heart Association
AHFSAmerican Hospital Formulary Service
aHRAdjusted hazard ratio
AI/ANAmerican Indian/Alaska Native
ALDAlcohol-associated liver disease; alcohol-related liver disease
ALPAlkaline phosphatase
ALTAlanine aminotransferase
AMDAdjusted mean difference versus placebo
ANCOVAAnalysis of covariance
APIAsian/Pacific Islander
APO-A, APO-B, APO-C3Apolipoprotein A, apolipoprotein B, apolipoprotein C3
ASTAspartate aminotransferase
ATEActive treatment extension
AUCArea under the curve
AUC0-τArea under the curve from time zero to the last measurable concentration
BCRPBreast cancer resistance protein
BCSBiopharmaceutics Classification System
BIDTwice daily
BIMsBudget impact models
BLBaseline
BMIBody mass index
BMSBristol Myers Squibb
BNPBrain natriuretic peptide
BPBlood pressure
BSA, BSAsBody surface area; share subscription warrants (bons de souscription d'actions)
BSEPBile salt export pump
CACalifornia
CAPControlled attenuation parameter
CASChemical Abstracts Service
CCCompensated cirrhosis
CD34Cluster of differentiation 34 (marker of liver sinusoidal endothelial cell capillarisation)
CDAA-HFDCholine-deficient, L-amino acid-defined, high-fat diet
CDCCenters for Disease Control and Prevention
CDMClinformatics Data Mart (Optum)
CHBChronic hepatitis B
CHCChronic hepatitis C
CIConfidence interval
CKDChronic kidney disease
CLDQChronic Liver Disease Questionnaire
CLDQ-MASHChronic Liver Disease Questionnaire, metabolic dysfunction-associated steatohepatitis version
CLDQ-NAFLDChronic Liver Disease Questionnaire, Non-Alcoholic Fatty Liver Disease version
CLDQ-NASHChronic Liver Disease Questionnaire, nonalcoholic steatohepatitis version
CMHCardiometabolic health
CO2Carbon dioxide
COVID-19Coronavirus disease 2019
CrICredible interval
CRNClinical Research Network
CRN-BClinical Research Network hepatocyte ballooning score
CRN-FClinical Research Network fibrosis score
CRN-IClinical Research Network lobular inflammation score
CRN-SClinical Research Network steatosis score
CRPC-reactive protein
CSClinically significant
CTComputed tomography
cT1Corrected T1 (iron-corrected T1 mapping by multiparametric MRI)
CTTQChia Tai Tianqing Pharmaceutical Group Co., Ltd.
CVCardiovascular
CVDCardiovascular disease
CVRMCardiovascular, renal, and metabolic
CYP, CYP450Cytochrome P450
CYP2B6Cytochrome P450 2B6
CYP2C19Cytochrome P450 2C19
CYP2C8Cytochrome P450 2C8
CYP2C9Cytochrome P450 2C9
CYP3A4Cytochrome P450 3A4
DALYsDisability-adjusted life years
dB/mDecibels per meter
DBPDiastolic blood pressure
DBPCDouble-blind placebo-controlled
DCCDecompensated cirrhosis
DCEDiscrete choice experiment
DEANDapagliflozin Efficacy and Action in NASH (phase 3 trial of dapagliflozin)
DILIDrug-induced liver injury
DMCData Monitoring Committee
DNLDe novo lipogenesis
DOADuration of approval
DPP-4, DPP-IVDipeptidyl peptidase 4
DPP-IViDipeptidyl peptidase 4 inhibitor
E167KGlutamate-to-lysine substitution at position 167 (TM6SF2 variant)
EASDEuropean Association for the Study of Diabetes
EASLEuropean Association for the Study of the Liver
EASOEuropean Association for the Study of Obesity
EC5050% effective concentration
ECGElectrocardiogram
eCRFElectronic case report form
EEAEuropean Economic Area
EFnoCEarly fibrosis (stage 0 to 2) without additional cardiovascular, renal, and metabolic comorbidities
EFwCEarly fibrosis (stage 0 to 2) with additional cardiovascular, renal, and metabolic comorbidities
EFXEfruxifermin
eGFREstimated glomerular filtration rate
EHRElectronic health record
ELFEnhanced Liver Fibrosis (test or score)
ELTREuropean Liver Transplant Registry
EMAEuropean Medicines Agency
EmaxMaximal effect
EoSEnd of study
EOTEnd of treatment
EQ-5DEuroQol 5-Dimension
EQ-5D-5LEuroQol 5-Dimension 5-Level
EREndoplasmic reticulum; emergency room
ETNB89bio, Inc. Nasdaq ticker symbol
EUEuropean Union
EU5France, Germany, Italy, Spain, and the United Kingdom
EudraCTEuropean Union Drug Regulating Authorities Clinical Trials Database
evLYsEqual value life years
F0Fibrosis stage 0 (no fibrosis)
F1Fibrosis stage 1
F1BFibrosis stage 1B
F2Fibrosis stage 2
F3Fibrosis stage 3 (bridging fibrosis)
F4Fibrosis stage 4 (cirrhosis)
FAFatty acid
FASFull analysis set
FASTFibroScan-AST score
FDAFood and Drug Administration
FFSFlinders Fatigue Scale
FGFasting glucose
FGF21Fibroblast growth factor 21
FIB-4, FIB4, Fib4Fibrosis-4 index
FILFasting insulin levels
FLFlorida
FPGFasting plasma glucose
GAINGlobal Assessment of the Impact of NASH (study)
GCEAGeneralized cost-effectiveness analysis
GFRGlomerular filtration rate
GGTGamma-glutamyl transferase
GIGastrointestinal
GIPGlucose-dependent insulinotropic polypeptide
GLP-1Glucagon-like peptide-1
GLP-1 RA, GLP-1RA, GLP-1-RA, GLP1RAGlucagon-like peptide-1 receptor agonist
GmbHGesellschaft mit beschränkter Haftung (limited liability company)
GMIGlucose management indicator
GSDGlycemic Status Assessment for Patients With Diabetes (HEDIS measure)
GSKGSK plc
GTGround truth
GW501516Reference PPARδ agonist compound
HbA1c, A1c, A1CHemoglobin A1c
HBPBHealth Benefit Price Benchmark
HCCHepatocellular carcinoma
HCP, HCPsHealth care professional; health care provider
HCSCHealth Care Service Corporation
HDLHigh-density lipoprotein
HDL-CHigh-density lipoprotein cholesterol
HDPEHigh-density polyethylene
HEDISHealthcare Effectiveness Data and Information Set
HGPHepatic glucose production
hHSCHuman hepatic stellate cell
HMWHigh-molecular-weight
HOMA-IRHomeostatic Model Assessment of Insulin Resistance
hPPARsHuman peroxisome proliferator-activated receptors
HRHazard ratio
HRQL, HRQoLHealth-related quality of life
HRUHealth care resource utilization
hs-CRPHigh-sensitivity C-reactive protein
HSCHepatic stellate cell
HSD17B13Hydroxysteroid 17-beta dehydrogenase 13
HTNHypertension
HTSHigh throughput screening
I148MIsoleucine-to-methionine substitution at position 148 (PNPLA3 variant)
IAInterim analysis
IASInterim Analysis Set
IC50Half-maximal inhibitory concentration
ICER, ICERsIncremental cost-effectiveness ratio; Institute for Clinical and Economic Review
ICFInformed consent form
IHTGIntrahepatic triglycerides
II, IM, MMPNPLA3 rs738409 genotypes (homozygous isoleucine, heterozygous isoleucine/methionine, homozygous methionine)
ILIsIntensive lifestyle interventions
IMPInvestigational Medicinal Product
IMSImage management system
INDInvestigational new drug (application)
INNInternational Nonproprietary Name
INRInternational Normalized Ratio
IQRInterquartile range
IRInsulin resistance
IRBInstitutional Review Board
ISInsulin sensitivity
ISHAK-FModified Ishak fibrosis score
ITTIntention-to-treat
IUInternational units
IV1197347, IV1197736, IV1537661Codes for the three major human metabolites of lanifibranor (benzothiazole ring-opened derivative, acyl glucuronide, and monohydroxylated metabolite, respectively)
IVA337, IVA 337Development code for lanifibranor
KiInhibition constant
kPaKilopascal
KSAKingdom of Saudi Arabia
LLanifibranor (LEGEND treatment arm)
L+ELanifibranor with empagliflozin (LEGEND treatment arm)
LBASLiver biopsy analysis set
LBMLean body mass
LDLLow-density lipoprotein
LDL-CLow-density lipoprotein cholesterol
LITMUSLiver Investigation: Testing Marker Utility in Steatohepatitis (consortium)
LoELevel of evidence
LSLeast squares; liver stiffness; intensive lifestyle intervention
LSELondon Stock Exchange
LSECLiver sinusoidal endothelial cell
LSM, LSMsLiver stiffness measurement
LTLiver transplantation
LVEFLeft ventricular ejection fraction
M30, M65Cytokeratin 18 fragments (M30, apoptosis marker; M65, total fragment)
MAMassachusetts
MACEMajor adverse cardiovascular events
MADMultiple ascending doses
MALFModerate-to-advanced liver fibrosis
MALOMajor adverse liver outcomes
MASHMetabolic dysfunction-associated steatohepatitis
MASLDMetabolic dysfunction-associated steatotic liver disease
MASTMRI-AST score (MRI-PDFF, MRE, and AST)
MCSMental component summary
MDR1Multidrug resistance protein 1
MDRDModification of Diet in Renal Disease
MedDRAMedical Dictionary for Regulatory Activities
MEFIBMRE combined with FIB-4
MetALDMASLD with increased alcohol intake (metabolic dysfunction and alcohol-associated liver disease)
MHMantel-Haenszel
mmHgMillimeters of mercury
MMP-2Matrix metalloproteinase 2
MMRMMixed model for repeated measures
MREMagnetic resonance elastography
MRIMagnetic resonance imaging
MRI-PDFFMagnetic resonance imaging proton density fat fraction
MRRMortality rate ratio
MRSMagnetic resonance spectroscopy
NAFLNonalcoholic fatty liver
NAFLDNonalcoholic fatty liver disease
NASNAFLD Activity Score
NASHNonalcoholic steatohepatitis
NASH CRN, NASH-CRNNASH Clinical Research Network
NATIVENASH Trial to Validate IVA337 Efficacy
NCHSNational Center for Health Statistics
NCQANational Committee for Quality Assurance
NCTNational Clinical Trial (ClinicalTrials.gov identifier)
NDANew Drug Application
NEJMThe New England Journal of Medicine
NHANESNational Health and Nutrition Examination Survey
NHWNon-Hispanic White
NILDA, NILDAsNoninvasive liver disease assessment
NIT, NITsNoninvasive test
NJNew Jersey
NMPANational Medical Products Administration (China)
NT-proBNPN-terminal pro b-type natriuretic peptide
NYNew York
NYHANew York Heart Association
NYSENew York Stock Exchange
OATP1B1/3Organic anion transporting polypeptide 1B1 and 1B3
OCAObeticholic acid
OCT2Organic cation transporter 2
OTCOver-the-counter
OTCQXOTCQX Best Market (United States over-the-counter market)
PPlacebo (LEGEND treatment arm)
P3NPN-terminal procollagen III peptide
PAPennsylvania (PA Health and Wellness); prior authorization
pan-PPARAgonist of all three peroxisome proliferator-activated receptor isoforms
PCSPhysical component summary
PDFFProton density fat fraction
PDGFPlatelet-derived growth factor
PFPhysical functioning
PharmDDoctor of Pharmacy
PIVENSPioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (trial)
PKPharmacokinetic
PMPerson-months (as in /100PM, per 100 person-months)
PMPMPer member per month
PNPLA3Patatin-like phospholipase domain-containing protein 3
PPPer protocol
PPAR, PPARsPeroxisome proliferator-activated receptor
PPARαPeroxisome proliferator-activated receptor alpha
PPARβ/δ, PPARδPeroxisome proliferator-activated receptor beta/delta
PPARγPeroxisome proliferator-activated receptor gamma
PPSPer protocol set
PRIMEPriority Medicines (European Medicines Agency scheme)
Pro-C3N-terminal type III collagen propeptide
PRO, PROsPatient-reported outcome
PTMPlacebo-matching tablets
PYPerson-years
Q1First quarter
Q4WEvery 4 weeks
QALY, QALYsQuality-adjusted life year
QDOnce daily
QOLQuality of life
QTQT interval (electrocardiogram)
QTcCorrected QT interval
RAReceptor agonist
RCT, RCTsRandomized controlled trial
RdRate of insulin-stimulated muscle glucose disposal
RHHBYRoche Holding AG OTCQX ticker symbol
RO, ROGRoche Holding AG SIX Swiss Exchange ticker symbols
RRRisk ratio
SADSingle ascending doses
SAFSteatosis-Activity-Fibrosis (scoring system)
SAF-ASAF activity score
SAPStatistical analysis plan
SARSaudi riyal
SASSafety analysis set
SATSubcutaneous adipose tissue
SCStandard care
SDStandard deviation
SEStandard error
SF-36Medical Outcomes Study 36-Item Short-Form Health Survey
SF-6DShort-Form 6-Dimension
SGLT-2iSodium-glucose cotransporter-2 inhibitors
SGLT2, SGLT-2Sodium-glucose cotransporter-2
SHTGSevere hypertriglyceridemia
SIXSIX Swiss Exchange
SLDSteatotic liver disease
SNPSingle nucleotide polymorphism
SOC, SoCStandard of care
SPLENDORSurgical Procedures and Long-term Effectiveness in NASH Disease and Obesity Risk (cohort study)
SRTRScientific Registry of Transplant Recipients
SUCRASurface under the cumulative ranking curve
SUSARSuspected Unexpected Serious Adverse Reaction
T2D, T2DMType 2 diabetes; type 2 diabetes mellitus
T3Third tranche (of the Inventiva structured financing)
TAAThioacetamide
TETransient elastography
TEAE, TEAEsTreatment-emergent adverse event
TGTriglycerides
THR-αThyroid hormone receptor alpha
THR-βThyroid hormone receptor beta
TIMP-1Tissue inhibitor of metalloproteinase-1
TM6SF2Transmembrane 6 superfamily member 2
TWTreatment week (TW4, TW12, TW24: treatment week 4, 12, 24)
TZDsThiazolidinediones
U/LUnits per liter
UGT, UGTsUridine 5'-diphospho-glucuronosyltransferase
UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, UGT2B15, UGT2B17Uridine 5'-diphospho-glucuronosyltransferase isoforms
UKUnited Kingdom
ULNUpper limit of normal
USUnited States
USAUnited States of America
USDUnited States dollars
V-1, V0, V1, V2, V3Study visits (V-1, screening visit; V0, randomization; V1 and V2, interim visits; V3, end of treatment visit)
VATVisceral adipose tissue
VCTE, VCTEsVibration-controlled transient elastography
VLDLsVery-low-density lipoproteins
vsVersus
Vz/FApparent volume of distribution
W24Week 24
WACWholesale acquisition cost
WHOWorld Health Organization
WPAI:SHPWork Productivity and Activity Impairment: Specific Health Problem
WSIWhole slide image
WTPWillingness to pay
α-SMAAlpha-smooth muscle actin